Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6115)	10/20/1998 10:41:00 PM
From: BigKNY3	Respond to of 9523

10/19/98 R & D Focus Drug News NA(1) A phase I trial has been initiated by Pfizer with Phytopharm's appetite suppressant, P 57. The trial will evaluate the safety and tolerance of the compound in healthy volunteers. P 57 is derived from an extract of a South African plant and was originally licensed by Phytopharm from the Council for Scientific and Industrial Research (CSIR) in South Africa.

To: BigKNY3 who wrote (6115)	10/21/1998 7:58:00 AM
From: James Baker	Respond to of 9523

BigKNY quote: Mr. Stansky is moving money from the small players of the business -- mainly biotech firms with bright ideas, a drug or two on the market and a lot of risk -- to drug majors and very large biotechs that have visibility and predictability of earnings. Among his top picks are such large-caps as Pfizer Inc., the maker of Viagra ; and Schering-Plough Corp., maker of a successful cholesterol control drug called Lipitor. ********************* BigK, maybe when this fund manager does his research he will learn about WARNER LAMBERT and their ownership of Lipitor ! Jim